# Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive Emergencies

Study · id `cardio:ct-nct04670809` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04670809](<https://clinicaltrials.gov/study/NCT04670809>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04670809

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 262 participants.

## Technical summary

Registry record NCT04670809. Randomized; single masking; primary purpose treatment. Start 2020-07-27 (actual); primary completion 2021-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 262 participants (planned count; ClinicalTrials.gov record NCT04670809, source copy `cardio:ctgov-nct04670809-2020-12-17`, retrieved 2026-10-26)
- Started: 2020-07-27 (actual) (ClinicalTrials.gov record NCT04670809, source copy `cardio:ctgov-nct04670809-2020-12-17`, retrieved 2026-10-26)
- Primary completion: 2021-08 (anticipated) (ClinicalTrials.gov record NCT04670809, source copy `cardio:ctgov-nct04670809-2020-12-17`, retrieved 2026-10-26)
- Completion: 2021-12 (anticipated) (ClinicalTrials.gov record NCT04670809, source copy `cardio:ctgov-nct04670809-2020-12-17`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04670809, source copy `cardio:ctgov-nct04670809-2020-12-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04670809-2020-12-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive Emergencies
- Condition: Hypertensive Emergency
- Intervention (Drug): Clevidipine Butyrate Injection
- Intervention (Drug): Ncardipine Hydrochloride Injection
- Lead sponsor: Nanjing Yoko Biomedical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of clevidipine emulsion injection compared with nicardipine in patients with hypertensive emergencies: a randomized, single-blind, positive-parallel-controlled, phase III clinical trial (`cardio:pubmed-41231022`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c72472d8d1ef0c5d03ad092c5516c774f31252849f8a3318eab4ebc7c9cdb6e7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
